5/17/2019  5:36:07 PM Chg. -0.040 Volume Bid5/17/2019 Ask5/17/2019 Market Capitalization Dividend Y. P/E Ratio
2.740EUR -1.44% 31,174
Turnover: 85,627.820
-Bid Size: - -Ask Size: - 30.25 mill.EUR 0.00% -

Business description

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases. MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200).
 

Management board & Supervisory board

CEO
-
Management board
Walter Miller, Dr. Matthias Baumann
Supervisory board
Oliver Krautscheid, Dr. med. Stefan M. Manth, Dr. Michael Schultz
 

Company data

Name: Mologen AG
Address: Fabeckstr. 30,D-14195 Berlin
Phone: +49-30-841788-0
Fax: +49-30-841788-50
E-mail: info@mologen.com
Internet: www.mologen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 69.51%
IPO date: 6/22/1998

Investor relations

Name: Claudia Nickolaus
IR phone: +49-30-841788-38
IR-Fax: -
IR e-mail: investor@mologen.com

Company calendar

CW 33 | 8/14/2019 Interim Report 2nd Quarter/6 Months
CW 34 | 8/22/2019 General Shareholder Meeting
CW 45 | 11/7/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
69.51%
Global Derivative Trading GmbH
 
20.13%
Deutsche Balaton Aktiengesellschaft
 
4.55%
Axxion S.A.
 
3.04%
SIGNAL IDUNA Krankenversicherung a.G.
 
2.77%